Mariana Nacht

Mariana Nacht has over 20 years of experience in the biotech industry with a focus in oncology. She helped build several successful biotech companies from the start. She was most recently CSO of Vivid Biosciences.

Prior roles include VP Cancer Biology at KDAc Therapeutics, as well as a member of the founding executive team and VP/Head of Biology at Padlock Therapeutics, which was acquired by Bristol-Myer Squibb in 2016. Mariana was also one of the first employees at Avila Therapeutics and was responsible for three programs that advanced from discovery to clinical development in the first 5 years. Avila was acquired by Celgene in 2012. Mariana started her biotech career at Genzyme.